Pinnacle3® Radiation Therapy Planning System is a software package intended to provide planning support for the treatment of disease processes. Pinnacle3® Radiation Therapy Planning System incorporates a number of fully integrated subsystems, including Pinnacle3 Proton, which supports proton therapy planning. The full Pinnacle3® Radiation Therapy Planning System software package provides planning support for the treatment of disease processes, utilizing photon, proton, electron and brachytherapy techniques.

Pinnacle3® Radiation Therapy Planning System assists the clinician in formulating a treatment plan that maximizes the dose to the treatment volume while minimizing the dose to the surrounding normal tissues. The system is capable of operating in both the forward planning and inverse planning modes. Plans generated using this system is used in the determination of the course of a patient's radiation treatment. They are to be evaluated, modified and implemented by qualified medical personnel.

Device Description

The Pinnacle3® Radiation Therapy Planning System (hereafter Pinnacle3® RTP System) provides radiation treatment planning for the treatment of benign or malignant diseases. When using the Pinnacle3® RTP System, qualified medical personnel may generate, review, verify, approve, print and export the radiation therapy plan prior to patient treatment. The Pinnacle3® RTP System can provide plans for various radiation therapy modalities including utilizing photon, proton, electron and brachytherapy techniques.

The Pinnacle3® RTP System is a software package that runs on an Oracle Server and is accessed through one (or more) client(s) or an Oracle UNIX workstation. The software package consists of a core software module (Pinnacle3) and optional software features, which are available through a licensing scheme. The device has network capability to other Pinnacle® RTP System workstations, thin client, and to both input and output devices via local area network (LAN) or wide area network (WAN).

AI/ML Overview

The provide text is a 510(k) premarket notification for the Philips Medical Systems (Cleveland), Inc. Pinnacle3® Radiation Therapy Planning System. This document focuses on demonstrating substantial equivalence to a predicate device and does not contain detailed information about the acceptance criteria and study proving device performance as typically understood for AI/ML devices.

Here's an analysis based on the information provided, highlighting what is present and what is not present:

Key Takeaways from the Document:

Device Type: This is a Radiation Therapy Planning System, a software package. It's not explicitly an AI/ML device in the sense of making diagnostic predictions or interpretations, although some features (like Auto-segmentation, Deformable Image Registration) could potentially leverage AI/ML techniques. The document describes it as "software" and emphasizes "physics modeling," "dose computation," and "optimization processes."
Focus on Substantial Equivalence: The primary goal of this 510(k) is to demonstrate that the updated Pinnacle3® RTP System (Version 16.0) is substantially equivalent to its predicate device (K130992). This pathway typically relies on comparing new features to existing, approved functionalities rather than extensive novel clinical effectiveness studies.
Verification Testing, Not Clinical Trials: The document explicitly states: "Clinical trials were not performed as part of the development of this product. Clinical testing on patients is not advantageous in demonstrating substantial equivalence or safety and effectiveness of the device since testing can be performed such that no human subjects are exposed to risk. Verification testing was performed as required per the risk analyses and demonstrated that no new risks were introduced with the modifications in this submission." This strongly indicates that the "study" proving the device meets acceptance criteria involved non-clinical verification testing rather than a traditional performance study with a test set, ground truth, and human experts.
Acceptance Criteria Mentioned but Details Lacking: The document states that "The results of these tests demonstrate that the Pinnacle3® RTP System met the acceptance criteria and is adequate for its intended use." However, what those specific acceptance criteria were (e.g., specific quantitative thresholds for dose calculation accuracy, registration accuracy, etc.) and the detailed results are not described in this summary.

Given the document's nature as a 510(k) summary focused on substantial equivalence and non-clinical verification, many of the requested items (especially those related to clinical performance studies, expert consensus, sample sizes for test/training sets, and AI-specific metrics) are not present or applicable in the provided text.

Here's how to fill out your requested table and information, with many entries indicating "Not Applicable" or "Not Provided" based on the document:

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria Category	Specific Acceptance Criteria (Not Provided in Detail)	Reported Device Performance (Summary from Text)
System Functionality	Not explicitly detailed (e.g., "dose calculation accuracy within X%").	"Software verification testing has demonstrated that the IMPT and DIR features of the Pinnacle3® RTP System performs as intended in the specified use."
Risk Mitigation	All identified risks are sufficiently mitigated.	"The risk management activities show that all risks are sufficiently mitigated and that the overall residual risk is acceptable."
Safety & Effectiveness	No new concerns regarding safety or effectiveness.	"No new concerns regarding safety or effectiveness have been raised by the introduction of the additional features."
Compliance with Standards	Compliance with IEC 62304 and ISO 14971.	"The Pinnacle® RTP System complies with the following international and FDA-recognized consensus standards: IEC 62304, ISO 14971."
Intended Use	Adequate for its intended use.	"The results of these tests demonstrate that the Pinnacle3® RTP System met the acceptance criteria and is adequate for its intended use."

2. Sample size used for the test set and the data provenance

Sample Size: Not provided. The verification testing likely used various defined test cases or phantoms rather than a "test set" of patient data in the typical sense of a clinical performance study for an AI device.
Data Provenance: Not applicable/not provided for patient data. The development and verification likely used simulated or phantom data, or possibly a limited set of de-identified patient data for specific test cases.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

Number of Experts: Not provided.
Qualifications of Experts: Not provided.
Note: Since this was primarily verification testing of a planning system rather than a diagnostic AI device, the "ground truth" would likely be established by engineering specifications, known physical properties (e.g., for dose calculations in phantoms), or clinical standards, rather than direct expert annotation of medical images for a test set.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Adjudication Method: Not applicable/none. The document describes "verification testing" against specified requirements and risk analyses, not a human reader study requiring adjudication.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

MRMC Study: No. The document explicitly states "Clinical trials were not performed." This type of study is typically done for AI-assisted diagnostic devices.
Effect Size: Not applicable.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Standalone Performance: While the system calculates and optimizes plans, the performance study described is non-clinical verification testing of the software's adherence to specifications and risk mitigation. The device is intended to "assist the clinician," and plans "are to be evaluated, modified and implemented by qualified medical personnel," indicating it's not a standalone diagnostic device but a tool for medical professionals. The verification testing itself would be "standalone" in the sense that the software's outputs were checked against expected results as part of the engineering validation.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

Type of Ground Truth: Not explicitly stated but inferred from "verification testing" and "risk analyses." Likely involved:
- Engineering Specifications: Outputs (e.g., calculated dose, image registration accuracy) compared against predefined numerical tolerances.
- Physics Models: Accuracy of dose calculations verified against established radiation physics models and experimental data from phantoms.
- Clinical Standards: Verification that the system generates plans that align with accepted clinical practices and safety parameters for radiation therapy.

8. The sample size for the training set

Sample Size for Training Set: Not applicable/not provided. This is a software planning system with physics models and optimization algorithms, not a machine learning model that relies on a "training set" in the conventional sense for image classification or prediction tasks. While some features like "Atlas Auto-Segmentation" or "Model-Based Segmentation" might involve pre-trained models, the document does not provide details on their training data.

9. How the ground truth for the training set was established

How Ground Truth was Established: Not applicable/not provided for a training set in the AI/ML context. If certain sub-features (e.g., auto-segmentation) use models, the method for establishing their "ground truth" for training is not disclosed in this document.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services - USA. The logo features a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" written around it. Inside the circle is a stylized image of three human profiles facing to the right, with flowing lines representing hair or clothing.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

February 9, 2017

Philips Medical Systems (Cleveland), Inc. % Michelle Godin, MS, RAC Sr. Manager, Regulatory Affairs 5520 Nobel Drive FITCHBURG WI 53711

Re: K170086

Trade/Device Name: Pinnacle Radiation Therapy Planning System Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: MUJ Dated: January 6, 2017 Received: January 10, 2017

Dear Ms. Godin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Michael D'Hara

For

Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Administration

s for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

Indications for Use

510(k) Number (if known)

K170086

Device Name

Pinnacle3® Radiation Therapy Planning System

Indications for Use (Describe)

Pinnacle3 Radiation Therapy Planning System is a software package intended to provide planning support for the treatment of disease processes. Pinnacle3@ Radiation Therapy Planning System incorporates a number of fully integrated subsystems, including Pinnacle' Proton, which supports proton therapy planning. The full Pinnacles® Radiation Therapy Planning System software package provides planning support for the treatment of disease processes, utilizing photon, proton, electron and brachytherapy techniques.

Pinnacle3 Radiation Therapy Planning System assists the clinician in formulating a treatment plan that maximizes the dose to the treatment volume while minimizing the dose to the surrounding normal tissues. The system is capable of operating in both the forward planning and inverse planning modes. Plans generated using this system is used in the determination of the course of a patient's radiation treatment. They are to be evaluated, modified and implemented by qualified medical personnel.

Type of Use (Select one or both. as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a ccllection of information unless it displays a currently valid OMB number."

FORM FDA 3881 (8/14)

Page 1 of 1

PSC Publishing Services (301) 443-6740 EF

Special 510(k) Premarket Notification -Pinnacle3® Radiation Therapy Planning (RTP) System

{3}------------------------------------------------

510(k) Summary

This 510(k) summary of safety and effectiveness information is prepared in accordance with 21 CFR 807.92.

Date Prepared:	January 6, 2017
Manufacturer:	Philips Medical Systems (Cleveland), Inc.5520 Nobel DriveFitchburg, WI 53711
Contact Person:	Michelle Godin, MS, RACPhone: 774.331.7499Email: michelle.godin@philips.com
Device Name:	Pinnacle3® Radiation Therapy Planning System
Software Release:	Version 16.0
Classification:	Classification Name: Accelerator, Linear, MedicalClassification: 21 CFR 892.5050Regulation Classification Panel: RadiologyDevice Class: IIProduct Code: MUJ
Predicate Device:	Trade Name: Pinnacle3® Radiation Therapy Planning SystemManufacturer: Philips Medical Systems (Cleveland), Inc.510(k) Clearance: K130992Classification Name: Accelerator, Linear, MedicalClassification: 21 CFR 892.5050Regulation Classification Panel: RadiologyDevice Class: IIProduct Code: MUJ

The Pinnacle3® Radiation Therapy Planning System (hereafter Pinnacle3® Device Description: RTP System) provides radiation treatment planning for the treatment of benign or malignant diseases. When using the Pinnacle3® RTP System, qualified medical personnel may generate, review, verify, approve, print and export the radiation therapy plan prior to patient treatment. The Pinnacle3® RTP System can provide plans for various radiation therapy modalities including utilizing photon, proton, electron and brachytherapy techniques.

The Pinnacle3® RTP System is a software package that runs on an Oracle Server and is accessed through one (or more) client(s) or an Oracle UNIX workstation. The software package consists of a core software module

{4}------------------------------------------------

(Pinnacle3) and optional software features, which are available through a licensing scheme. The device has network capability to other Pinnacle® RTP System workstations, thin client, and to both input and output devices via local area network (LAN) or wide area network (WAN).

Image data is imported from CT, MR, PET, PET-CT and SPECT devices using a DICOM-compliant interface. A qualified medical professional uses the Pinnacle3® RTP System for functions such as viewing and analyzing the patient's anatomy, and generating a radiation therapy plan. The following are examples of tasks that may be performed by clinicians when using the base features of the Pinnacle3® RTP system:

Perform proton, photon, and electron physics modeling, dose algorithm and machine commissioning.
Evaluate the treatment plan based on radiation-sensitive structures and the tumor.
Combine both geometric and dosimetric planning on the same ● platform, including CT simulation data and plans.
. Configure beam variables such as energy, geometry, and beam modifiers such as blocks, wedges, multi-leaf collimators, bolus, aperture and compensators.
Visualize the beam on a display, initiate the dose computation, and set the weight of each beam.
Obtain dose values at any Points of Interest (POI).
Evaluate Digitally Reconstructed Radiographs (DRRs) . on Pinnacle3® RTP or remote system using DICOM Secondary Capture (SC) Export.

Once complete, the Pinnacle3® RTP System has the ability to transfer the finished plan to other devices used in the therapy process such as an Oncology Information System (OIS), Linear Accelerator (Linac), and/or 3rd Party QA systems.

The following optional Pinnacle3® RTP System features are available to assist the clinician with the radiation therapy planning process. These features are an integrated part of the Pinnacle3® RTP System and represent a subset of the optional features available to the user via licensing. Corresponding instructions for use such as User Guides or Release Notes are also provided to the clinician for each optional feature.

Pinnacle3 Proton

Pinnacle3 Proton provides support for Uniform Scanning and Double Scatter proton delivery devices. The system allows machine modeling and commissioning for machine definition. The system allows the user to utilize a commissioned machine for treatment planning purposes. The feature includes proton dose computation, and each beam is shaped using an aperture and a compensator.

{5}------------------------------------------------

Intensity Modulated Proton Therapy (IMPT):

IMPT provides support for Spot Scanning proton delivery devices. The system allows machine modeling and commissioning for machine definition. The system allows the user to utilize a commissioned machine for treatment planning purposes. The feature includes proton dose computation, and the beam dose is shaped by optimizing the relative weights applied to a spot pattern.

P3IMRT (Intensity Modulated Radiation Therapy):

P3IMRT combines both forward and inverse planning functionality. The system determines a plan that satisfies the user's treatment goals through an optimization process. The user's treatment goals are specified as objectives and constraints based on dose distribution characteristics.

Direct Machine Parameter Optimization (DMPO):

DMPO is a method of performing IMRT where Multi-Leaf Collimator (MLC) settings are produced directly within the optimization process.

Smart Arc:

SmartArc is a method of performing IMRT for linear accelerators that are capable of delivering intensity modulated arc treatments.

Syntegra (also referred to as AutoFusion):

Syntegra automates multi-modality image registration and fusion by overlaying images from CT, MR, PET, PET-CT and SPECT devices using a DICOM-compliant interface. This feature provides clinicians with the ability to relate, interpret and contour an image's anatomic and functional information.

Deformable Image Registration (DIR):

DIR provides the ability to create a Displacement Vector Field (DVF) based on a user-defined initial rigid registration between two CT images. DIR also introduces the tools that can be used to validate and approve the DVF, and the ability to apply the DVF to a CT image volume or a dose distribution.

Model-Based Segmentation (MBS):

MBS is library of individual organ models that provide a starting point for the contouring of individual Regions of Interest (ROIs).

Atlas Auto-Segmentation:

Atlas is a collection of organs models that are specific to an anatomical region and provide a starting point for Autosegmentation of an image data set. Auto-segmentation uses an algorithm-based process that customizes the shape of each organ model into a set of ROIs that map to the patient anatomy.

{6}------------------------------------------------

Dynamic Planning:

Dynamic Planning provides the ability to transfer an entire treatment plan from one CT image to another. Also included is the ability to deform the ROIs from the original image to conform to the anatomy of the new image and the ability to store the ROIs and dose from the original plan in a read-only record that is viewable within the new plan.

Auto-Planning:

Auto-Planning automates a significant portion of the DMPO and SmartArc treatment planning process, providing major time and clinical efficiency gains to customers while also improving treatment plan quality and consistency. Auto-Planning includes the ability to customize, store, and apply templates that facilitate the planning and plan evaluation processes.

AcQSim3:

AcQSim3 provides the tumor localization features that can be utilized at the time of scan acquisition or at the time of treatment. AcQSim3 is an integrated module that is accessible from within the Pinnacle3 planning application.

Tumor LOC:

Tumor LOC provides the tumor localization features that can be utilized at the time of scan acquisition. Tumor LOC is accessible directly from the console system connected to a CT scanner, and is remotely connected to the Pinnacle3 patient database.

In addition to the above, the following software options are available to facilitate image and/or data import and export between radiation therapy devices such as the imaging camera, Pinnacle3® RTP System, and Record & Verify system. DICOM is the acronym for Digital Imaging and Communications in Medicine and is an internationally recognized standard for transferring biomedical information such as images and data between devices or over a network.

DICOM RT:

DICOM RT software is used to support both Structure Set and Radiation Therapy Plan import and export functions. Structure Sets describe regions and points of interest to other systems. Plan information includes beam geometry and delivery information.

DICOM Image:

DICOM Image software is used to support image import and export to and from the Pinnacle3® RTP System workstation according to the NEMA DICOM standard, version 3.0. This functionality allows diagnostic imaging devices supporting the DICOM 3.0 standard to interface with the Pinnacle3® RTP System.

{7}------------------------------------------------

Indications forUse:	The Indications for Use statement for the Pinnacle3® RTP System is asfollows.
	Pinnacle3® Radiation Therapy Planning System is a softwarepackage intended to provide planning support for the treatment ofdisease processes. Pinnacle3® Radiation Therapy Planning Systemincorporates a number of fully integrated subsystems, includingPinnacle3 Proton, which supports proton therapy planning. The fullPinnacle3® Radiation Therapy Planning System software packageprovides planning support for the treatment of disease processes,utilizing photon, proton, electron and brachytherapy techniques.
	Pinnacle3®Radiation Therapy Planning System assists theclinician in formulating a treatment plan that maximizes the doseto the treatment volume while minimizing the dose to thesurrounding normal tissues. The system is capable of operating inboth the forward planning and inverse planning modes. Plansgenerated using this system is used in the determination of thecourse of a patient's radiation treatment. They are to be evaluated,modified and implemented by qualified medical personnel.
	Based on the information provided above, the Indications for Use of thePinnacle3® Radiation Therapy Planning System remains unchanged fromthe predicate device (K130992, June 14, 2013), thus demonstratingsubstantial equivalence.
FundamentalScientificTechnology:	The Pinnacle3® RTP System provides radiation treatment planning supportfor the treatment of disease processes, utilizing photon, proton, electron, andbrachytherapy techniques.
	The Pinnacle3 Proton feature supports intensity-modulated treatmenttechniques on spot scanning delivery devices (Intensity Modulated ProtonTherapy). The Intensity Modulated Proton Therapy (IMPT) featuresinclude physics modeling for spot scanning delivery, proton pencil beamdose computation, proton pencil beam optimization, robust analysis, androbust optimization. These features allow the user to create robust protonplans that take full advantage of spot scanning proton delivery techniques.
	The Syntegra feature (the current image registration solution) now includesDeformable Image Registration (DIR). The DIR software supports thedeformation of Computed Tomography (CT) image volumes and dosevolumes. The DIR features include CT image deformation, dosedeformation, and a variety of QA tools to evaluate the quality of thedeformation. These features allow the user to evaluate a prior treatmentagainst a new CT image to assist in the treatment decision process.
	The IMPT features are conceptually similar to proton features in thepredicate device, Pinnacle3® RTP System (Pinnacle3 Proton), with the maindifferences pertaining only to the modeling and planning features necessaryto accommodate the machine characteristics. The features introduced with
Summary ofNon-ClinicalPerformanceData:	The Pinnacle® RTP System complies with the following international and FDA-recognized consensus standards:- Consensus Standard IEC 62304 (Edition 1.0, 2006) – Medical Device

{8}------------------------------------------------

DIR are a direct extension of existing functionality in the predicate device, Pinnacle3® RTP System (Syntegra).

Based on the information provided above, the Pinnacle30 RTP System is considered substantially equivalent to the predicate device (K130992, June 14, 2013) in terms of fundamental scientific technology.

Software Software Life Cycle Processes. ● Consensus Standard ISO 14971 (2007, 2012) - Medical devices -Application of Risk Management to Medical Devices
Software verification testing has demonstrated that the IMPT and DIR features of the Pinnacle3® RTP System performs as intended in the specified use. The risk management activities show that all risks are sufficiently mitigated and that the overall residual risk is acceptable. No new concerns regarding safety or effectiveness have been raised by the introduction of the additional features to the Pinnacle3® RTP System.

Therefore, the Pinnacle3® RTP System is substantially equivalent to the predicate device (K130992, June 14, 2013) in terms of safety and effectiveness.

Summary of Clinical trials were not performed as part of the development of this product. Clinical Clinical testing on patients is not advantageous in demonstrating substantial Performance equivalence or safety and effectiveness of the device since testing can be Data: performed such that no human subjects are exposed to risk. Verification testing was performed as required per the risk analyses and demonstrated that no new risks were introduced with the modifications in this submission.

The Pinnacle3® RTP System is substantially equivalent to the predicate device Substantial Equivalence (K130992, June 14, 2013) in terms of design features, fundamental scientific Conclusion: technology, indications for use, and safety and effectiveness. A risk analysis was completed for the IMPT and DIR features of the proposed device, Pinnacle3® RTP System software version 16.0, and all hazards related to safety or effectiveness were mitigated as appropriate. Verification testing, specifically to address any safety or effectiveness concerns, was completed in compliance with Philips procedures and with the requirements specified in the international and FDA recognized consensus standards. The results of these tests demonstrate that the Pinnacle3® RTP System met the acceptance criteria and is adequate for its intended use.

Regulation Number and Section

§ 892.5050 Medical charged-particle radiation therapy system.

(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.